Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2015

View Archived Issues

Genomic analysis of PDXs to identify resistance/response mechanisms to anti-EGFR in CRC

Genetic profiling of early lung neoplasms, primary lung tumors and circulating DNA

Precision medicine to identify genes influencing response to hydrochlorothiazide

Results from UK Biobank initiative identify new genes for respiratory disorders

Novel mutations causing Hunter syndrome identified in case series report

Actelion Pharmaceuticals divulges CXCR3 modulators

Merck & Co. reports HIV reverse transcriptase inhibitors

NIH awards several grants to Aridis

Izun Pharmaceuticals reports data from phase II trial in diabetic foot ulcers

Preclinical data on VS-105's effect on BMD

NPSP-795 shows promise for ADH1

Institute of Human Virology begins phase I trial of HIV vaccine candidate

Theravance submits IND for neprilysin inhibitor TD-0714

3SBio enters licensing deal with Alteogen for ALT-P7 in China

GNI subsidiary files NDA in China for Amnolake

Synjardy now available in U.S. pharmacies

Baricitinib demonstrates superiority to adalimumab in phase III study

FDA awards QIDP designation to Mino-Lok

Astex Therapeutics reports FGFR inhibitors

Merck & Co. patents TrkA inhibitors

Chinese Ebola vaccine enters first overseas trial

Roche discloses autotaxin inhibitors

Pfizer and UICC award 20 grants to support projects in metastatic breast cancer

Protalix sells share in Elelyso collaboration agreement to Pfizer

Merck KGaA relaunches brand identity

Bristol-Myers Squibb and Five Prime sign CSF-1R antibody license and collaboration agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...